Novartis (NOVN SW) CEO warns reality of Trump's drug pricing policy will set in over 'the next 18 months'
Context
The Novartis CEO's warning regarding the implications of Trump's drug pricing policy suggests potential shifts in the pharmaceutical landscape, particularly affecting pricing strategies and profitability within the U.S. market. This could lead to market volatility, especially in equities related to the pharmaceuticals sector, as investors adjust their expectations on earnings and growth. The broader geopolitical context could also influence currency markets, particularly for the USD and EUR, as policies affect trade and investment flows.
Trade the TapeGet this analysis live, the moment it breaksNewsquawk's real-time dashboard delivers market-moving headlines and instant context to your desk before the rest of the market reacts.
Open Dashboard#UNITED STATES#USD#SWITZERLAND#EUR#JAPAN#JPY#UNITED KINGDOM#GBP#EUROPE#NOVARTIS AG#FOREX#EQUITIES#ENERGY#EU SESSION#WTI#COMMODITIES#PHARMACEUTICALS#PHARMACEUTICALS (GROUP)#PHARMACEUTICALS, BIOTECHNOLOGY & LIFE SCIENCES#SWISS MARKET INDEX#NOVN#DXY#TRUMP#EUROPEAN EQUITIES